Comparison of allergic lung disease in three mouse strains after systemic or mucosal sensitization with ovalbumin antigen

2009 ◽  
Vol 61 (3) ◽  
pp. 199-207 ◽  
Author(s):  
Weiyan Zhu ◽  
M. Ian Gilmour
2006 ◽  
Vol 36 (9) ◽  
pp. 1109-1114 ◽  
Author(s):  
N. Hizawa ◽  
M. Kawaguchi ◽  
S.-K. Huang ◽  
M. Nishimura

2006 ◽  
Vol 291 (5) ◽  
pp. L1005-L1017 ◽  
Author(s):  
Irving C. Allen ◽  
Amy J. Pace ◽  
Leigh A. Jania ◽  
Julie G. Ledford ◽  
Anne M. Latour ◽  
...  

A genetic contribution to asthma susceptibility is well recognized, and linkage studies have identified a large number of genes associated with asthma pathogenesis. Recently, a locus encoding a seven-transmembrane protein was shown to be associated with asthma in founder populations. The expression of the protein GPRA (G protein-coupled receptor for asthma susceptibility) in human airway epithelia and smooth muscle, and its increased expression in a mouse model of asthma, suggested that a gain-of-function mutation in this gene increased the disease risk. However, we report here that the development of allergic lung disease in GPRA-deficient mice is unaltered. A possible explanation for this finding became apparent upon reexamination of the expression of this gene. In contrast to initial studies, our analyses failed to detect expression of GPRA in human lung tissue or in mice with allergic lung disease. We identify a single parameter that distinguishes GPRA-deficient and wild-type mice. Whereas the change in airway resistance in response to methacholine was identical in control and GPRA-deficient mice, the mutant animals showed an attenuated response to thromboxane, a cholinergic receptor-dependent bronchoconstricting agent. Together, our studies fail to support a direct contribution of GPRA to asthma pathogenesis. However, our data suggest that GPRA may contribute to the asthmatic phenotype by altering the activity of other pathways, such as neurally mediated mechanisms, that contribute to disease. This interpretation is supported by high levels of GPRA expression in the brain and its recent identification as the neuropeptide S receptor.


2012 ◽  
Vol 44 (8) ◽  
pp. 470-484 ◽  
Author(s):  
Alessandra Livraghi-Butrico ◽  
Barbara R. Grubb ◽  
Elizabeth J. Kelly ◽  
Kristen J. Wilkinson ◽  
Huifang Yang ◽  
...  

Mucus clearance is an important airway innate defense mechanism. Airway-targeted overexpression of the epithelial Na+channel β-subunit [encoded by sodium channel nonvoltage gated 1, beta subunit ( Scnn1b)] in mice [ Scnn1b-transgenic (Tg) mice] increases transepithelial Na+absorption and dehydrates the airway surface, which produces key features of human obstructive lung diseases, including mucus obstruction, inflammation, and air-space enlargement. Because the first Scnn1b-Tg mice were generated on a mixed background, the impact of genetic background on disease phenotype in Scnn1b-Tg mice is unknown. To explore this issue, congenic Scnn1b-Tg mice strains were generated on C57BL/6N, C3H/HeN, BALB/cJ, and FVB/NJ backgrounds. All strains exhibited a two- to threefold increase in tracheal epithelial Na+absorption, and all developed airway mucus obstruction, inflammation, and air-space enlargement. However, there were striking differences in neonatal survival, ranging from 5 to 80% (FVB/NJ<BALB/cJ<C3H/HeN<C57BL/6N), which correlated with the incidence of upper airway mucus plugging and the levels of Muc5b in bronchoalveolar lavage. The strains also exhibited variable Clara cell necrotic degeneration in neonatal intrapulmonary airways and a variable incidence of pulmonary hemorrhage and lung atelectasis. The spontaneous occurrence of a high surviving BALB/cJ line, which exhibited delayed onset of Na+hyperabsorption, provided evidence that: 1) air-space enlargement and postnatal death were only present when Na+hyperabsorption occurred early, and 2) inflammation and mucus obstruction developed whenever Na+hyperabsorption was expressed. In summary, the genetic context and timing of airway innate immune dysfunction critically determines lung disease phenotype. These mouse strains may be useful to identify key modifier genes and pathways.


2015 ◽  
Vol 59 (4) ◽  
pp. 2129-2135 ◽  
Author(s):  
Claire Andréjak ◽  
Deepak V. Almeida ◽  
Sandeep Tyagi ◽  
Paul J. Converse ◽  
Nicole C. Ammerman ◽  
...  

ABSTRACTTheMycobacterium aviumcomplex is the most common cause of nontuberculous mycobacterial lung disease worldwide; yet, an optimal treatment regimen forM. aviumcomplex infection has not been established. Clarithromycin is accepted as the cornerstone drug for treatment ofM. aviumlung disease; however, good model systems, especially animal models, are needed to evaluate the most effective companion drugs. We performed a series of experiments to evaluate and use different mouse models (comparing BALB/c, C57BL/6, nude, and beige mice) ofM. aviuminfection and to assess the anti-M. aviumactivity of single and combination drug regimens,in vitro,ex vivo, and in mice.In vitro, clarithromycin and moxifloxacin were most active againstM. avium, and no antagonism was observed between these two drugs. Nude mice were more susceptible toM. aviuminfection than the other mouse strains tested, but the impact of treatment was most clearly seen inM. avium-infected BALB/c mice. The combination of clarithromycin-ethambutol-rifampin was more effective in all infected mice than moxifloxacin-ethambutol-rifampin; the addition of moxifloxacin to the clarithromycin-containing regimen did not increase treatment efficacy. Clarithromycin-containing regimens are the most effective forM. aviuminfection; substitution of moxifloxacin for clarithromycin had a negative impact on treatment efficacy.


Sign in / Sign up

Export Citation Format

Share Document